China Advanced Treatment Updates

China Advanced Treatment Updates is a CareNavigator source-led editorial column for short updates on advanced treatment developments in China, including oncology innovation, cell therapy, hospital research, regulatory approvals, and clinical programs that may matter to international patients and families.

These updates are based on public sources such as hospital announcements, official media, regulators, journals, academic institutions, or company disclosures. They are not hospital rankings, treatment recommendations, or medical advice.

Each update explains what happened, why it matters, what international patients should understand, what it does not mean, and how CareNavigator can help families evaluate whether a China-based pathway may be relevant to discuss with qualified medical teams.

Recent updates: EVO+ ICL (V5) in Shanghai: What International Patients Should Know About Technology and Cost: https://carenavigator.io/insights/evo-plus-icl-v5-shanghai-international-patients
Shanghai-Kashgar Expert Review Supports a Rare Craniofacial Case From Kazakhstan: https://carenavigator.io/insights/shanghai-kashgar-remote-review-kazakhstan-craniofacial-case
Shanghai Reports First Post-Approval Implant of NEO Brain-Computer Interface System: https://carenavigator.io/insights/shanghai-neo-brain-computer-interface-first-post-approval-implant
Jiahui Reports First International Patient T-Cell Collection After China's Approval of Solid-Tumor CAR-T Therapy: https://carenavigator.io/insights/jiahui-international-patient-solid-tumor-car-t-collection-update
China Approves EGFR×HER3 Bispecific ADC for Previously Treated Recurrent or Metastatic Nasopharyngeal Cancer: https://carenavigator.io/insights/china-egfr-her3-bispecific-adc-nasopharyngeal-cancer-update
Sanlian Lifeweek Reports How Brain-Computer Interface Research Is Helping a Spinal Cord Injury Patient Rebuild Daily Life in China: https://carenavigator.io/insights/china-brain-computer-interface-spinal-cord-injury-update
China-Originated Oncology Research Gains Attention at ASCO 2026: https://carenavigator.io/insights/china-oncology-innovation-asco-2026-update
World's First Solid-Tumor CAR-T Cell Therapy Product Approved in China: https://carenavigator.io/insights/china-claudin18-car-t-gastric-cancer-approval
Guangzhou Concord Reports Skull-Base Proton Therapy for Olfactory Neuroblastoma: https://carenavigator.io/insights/guangzhou-concord-proton-olfactory-neuroblastoma-update
China Advanced Treatment Update: Ruijin Hospital's PSB202 Study Highlights a New China-Originated Pathway for Relapsed B-cell Lymphoma: https://carenavigator.io/insights/ruijin-psb202-b-cell-lymphoma-update
Shanghai Doctors Use a 5G Remote Robot to Perform Kidney Cancer Surgery for a Patient in Tibet: https://carenavigator.io/insights/shanghai-5g-remote-robot-kidney-cancer-surgery-tibet
AENEAS 2 Study Reports 10-Month Progression-Free Survival Extension: The Lancet Oncology Publishes Shanghai Chest Hospital Team's Phase III Trial: https://carenavigator.io/insights/shanghai-chest-hospital-aeneas-2-lung-cancer-update
Pancreatic Cancer Patient Had Acute Pancreatitis Twice: Shanghai Doctors Complete a Difficult Tumor Resection: https://carenavigator.io/insights/zhongshan-hospital-pancreatic-cancer-surgery-timing-update

CareNavigator helps patients organize records, understand whether a reported China-based pathway may be relevant, and prepare for informed conversations with qualified medical teams. Patient eligibility, risks, benefits, availability, and treatment decisions should be assessed by licensed clinicians and the responsible medical institution.